Featured news from NHIVNA

HIV-related news from NAM

Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most
Liz Highleyman, 2016-07-26 09:20:00

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilised after a year and those who stopped taking it began to see a reversal of the decline, researchers reported last week at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. Another study found that clinically relevant declines in kidney function among Truvada PrEP users are rare and monitoring every six months is adequate for most people.

Tenofovir disoproxil fumarate (TDF; Viread) is one of the most widely used antiretrovirals for HIV treatment and the Truvada (tenofovir/emtricitabine) co-formulation is increasingly used for HIV prevention. Tenofovir is considered generally safe and well tolerated, but it may cause a small amount of bone loss soon after starting and can lead to kidney problems in susceptible individuals.